drugset / Trial / NCT05483530
A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and tolerability of HLX60 combined with HLX10 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy for each combination regimen.
Timeline
- Start
- 2022-12-14
- Primary completion
- 2024-12
- Completion
- 2025-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX60 | Monoclonal antibody | — | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.